Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Chronic treatment with C-type natriuretic peptide impacts differently in the aorta of normotensive and hypertensive rats.

Caniffi C, Cerniello FM, Bouchet G, Sueiro ML, Tomat A, Maglio DG, Toblli JE, Arranz C.

Pflugers Arch. 2019 Aug;471(8):1103-1115. doi: 10.1007/s00424-019-02287-y. Epub 2019 Jun 11.

PMID:
31187260
2.

Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model.

Maglio D, Sun HK, Patel T, Banevicius MA, Nightingale CH, Arya A, Wang G, Chen Z, Phan LT, Nicolau DP.

Int J Antimicrob Agents. 2014 Jun;43(6):540-6. doi: 10.1016/j.ijantimicag.2014.01.029. Epub 2014 Mar 19.

PMID:
24703590
3.

Time-course evaluation and treatment of skin inflammatory immune response after ultraviolet B irradiation.

Paz ML, Ferrari A, Weill FS, Leoni J, Maglio DH.

Cytokine. 2008 Oct;44(1):70-7. doi: 10.1016/j.cyto.2008.06.012. Epub 2008 Aug 16.

PMID:
18710815
5.

Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.

Sun HK, Lee SY, Banevicius MA, Du X, Maglio D, Nicolau DP.

J Antimicrob Chemother. 2005 Sep;56(3):559-65. Epub 2005 Jul 15.

PMID:
16024590
6.

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.

DeRyke CA, Maglio D, Nicolau DP.

Expert Opin Pharmacother. 2005 Jun;6(6):873-89. Review.

PMID:
15952918
7.

The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.

Maglio D, Nicolau DP.

Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):781-8. Review.

PMID:
15672121
8.

Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.

Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2005 Jan;49(1):276-80.

9.

Macrolide resistance in Streptococcus pneumoniae: mechanisms, patterns, and clinical implications of resistance.

Sun H, Maglio D, Nicolau D.

Conn Med. 2004 Oct;68(9):571-6. Review. No abstract available.

PMID:
15532438
10.

Differential efficacy of clarithromycin in lung versus thigh infection models.

Maglio D, Capitano B, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP.

Chemotherapy. 2004 Jun;50(2):63-6.

PMID:
15211079
11.

Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Maglio D, Ong C, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2004 Jun;48(6):1941-7.

12.

Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance.

Maglio D, Capitano B, Banevicius MA, Tessier PR, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2004 May;23(5):498-501.

PMID:
15120730
13.

Characterization of the penetration of garenoxacin into the breast milk of lactating women.

Amsden GW, Nicolau DP, Whitaker AM, Maglio D, Bello A, Russo R, Barros A Jr, Gajjar DA.

J Clin Pharmacol. 2004 Feb;44(2):188-92.

PMID:
14747428
14.

Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides.

Maglio D, Nicolau DP, Nightingale CH.

Infect Dis Clin North Am. 2003 Sep;17(3):563-77, vi. Review.

PMID:
14711077
15.

Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model.

Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2003 Dec;22(6):588-93.

PMID:
14659656
16.

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2003 Aug;23(8):988-91.

PMID:
12921245
17.

Production and resolution of cantharidin-induced inflammatory blisters.

Maglio D, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2003 Jul;22(1):77-80.

PMID:
12842333
18.

Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Maglio D, Teng R, Thyrum PT, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2003 May;47(5):1771-3.

19.

Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.

Kuti JL, Maglio D, Nightingale CH, Nicolau DP.

Am J Health Syst Pharm. 2003 Mar 15;60(6):565-8.

PMID:
12659058
20.

Pleconaril, a novel antipicornaviral agent.

Florea NR, Maglio D, Nicolau DP.

Pharmacotherapy. 2003 Mar;23(3):339-48. Review.

PMID:
12627933
21.

Extended interval aminoglycoside dosing: from concept to clinic.

Maglio D, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2002 Apr;19(4):341-8. Review.

PMID:
11978505
22.

Drotrecogin alfa (activated) for severe sepsis.

Maglio D.

Conn Med. 2002 Mar;66(3):145-50. Review. No abstract available.

PMID:
11957766

Supplemental Content

Loading ...
Support Center